DrugPatentWatch Database Preview
Litigation Details for AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2018)
» See Plans and Pricing
AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2018)
| Docket | Start Trial | Date Filed | 2018-05-01 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ZYDUS PHARMACEUTICALS (USA) INC. | ||
| Patents | 6,414,126; 6,515,117; 7,851,502; 7,919,598; 8,221,786; 8,361,972; 8,501,698; 8,685,934; 8,716,251 | ||
| Attorneys | Christopher J. Cassella | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc.
The small molecule drugs covered by the patents cited in this case are Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , and Start Trial .
Details for AstraZeneca AB v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-06-22 | 11 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,851,502 ;7,919,598 ;8,221,786… 1 May 2018 1:18-cv-00664 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-01-24 | 33 | Without Prejudice All Claims Concerning U.S. Patent Nos. 7,851,502, 7,919,598, 8,221,786, 8,361,972, 8,501,… 1 May 2018 1:18-cv-00664 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-01-27 | 34 | Without Prejudice All Claims Concerning U.S. Patent Nos. 7,851,502, 7,919,598, 8,221,786, 8,361,972, 8,501,… 1 May 2018 1:18-cv-00664 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-03-13 | 37 | Complaint - Amended | expiration of U.S. Patent Nos. 6,414,126 (“the ’126 patent”) 6,515,117 (“the ’117 patent”), and 8,685,934… This is an action for patent infringement arising under the patent laws of the United States, … FIRST COUNT FOR PATENT INFRINGEMENT (’126 PATENT) 17. AstraZeneca realleges… 18. The U.S. Patent and Trademark Office (“PTO”) issued the ’126 patent on July 2, 2002, entitled… The ’126 patent expires on October 4, 2020, excluding any pediatric exclusivity or patent term extension | External link to document |
| 2019-03-14 | 38 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,414,126 ;6,515,117 ;8,685,934… 1 May 2018 1:18-cv-00664 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2018-05-01 | 4 | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,614,126 ;6,515,117. (crb) (Entered… 1 May 2018 1:18-cv-00664 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-10-11 | 70 | Notice of Service | Claim Construction of Certain Terms of U.S. Patent Nos. 6,414,126 and 6,515,117 filed by AstraZeneca AB.(Silver… 1 May 2018 1:18-cv-00664 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
